


Attorney Docket No.: 56476 (71661)
U.S.S.N.: 09/964,260
Inventors: Oxford, et al.
Filed: September 26, 2001
Page 2 of 11

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1 (original): A compound of general formula I:



wherein

each of R¹ and R² independently represents a C₁₋₆ alkyl or C₂₋₇ acyl group;
R⁵ represents a hydrogen atom or a C₁₋₃ alkyl, C₂₋₃ alkenyl or C₂₋₃ alkynyl group;
R⁶ represents a hydrogen atom or a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, amino, C₁₋₆ alkylamino, di(C₁₋₆) alkylamino or C₂₋₇ acylamino group;
each of R⁷ and R⁸ independently represents a hydrogen or halogen atom or a hydroxy, trifluoromethyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₂₋₇ acyl, C₁₋₆ alkylthio, C₁₋₆ alkoxy, C₃₋₆ cycloalkyl; and
R⁹ represents a hydrogen or halogen atom or a hydroxy, trifluoromethyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₂₋₇ acyl, C₁₋₆ alkylthio, C₁₋₆ alkoxy or C₃₋₆ cycloalkyl group;
X represents OCH₂ or a group CR³R⁴, wherein each of R³ and R⁴ independently represents a hydrogen atom or a C₁₋₃ alkyl group;

Attorney Docket No.: 56476 (71661)
U.S.S.N.: 09/964,260
Inventors: Oxford, et al.
Filed: September 26, 2001
Page 3 of 11

each of R¹⁰ and R¹¹ independently represents a hydrogen atom, a C₁₋₃ alkyl, C₃₋₆ cycloalkyl or phenyl group;

Y represents an oxygen atom or a group CHNO₂, NCN, NH or NNO₂;

n is an integer from 2 to 4;

or a salt thereof.

Claim 2 (currently amended): A compound of general formula I wherein, independently or in any compatible combination:

each of R¹ and R² represents a C₁₋₆ alkyl, preferably a C₁₋₄ alkyl, group;

R¹ and R² are the same as each other;

each of R³ and R⁴ represents a hydrogen atom;

R⁵ represents a hydrogen atom;

R⁶ represents a hydrogen atom;

each of R⁷ and R⁸ represents a C₁₋₆ alkyl, preferably methyl, ethyl or isopropyl, group;

R⁷ and R⁸ are the same as each other;

R⁹ represents a halogen atom or a methyl or acetyl group;

Y represents an oxygen atom or a group CHNO₂; and

n is 2.

Claim 3 (original): 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one.

Claim 4 (original): 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[N-(N'-isopropylcarbamoyl)-2-aminoethyl]-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one.

Attorney Docket No.: 56476 (71661)
U.S.S.N.: 09/964,260
Inventors: Oxford, et al.
Filed: September 26, 2001
Page 4 of 11

Claim 5 (original): 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[N-[1-(N'-methyl-2-nitroethenamine)]-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one.

Claim 6 (original): 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3- [N-[1-(*N*'-isopropyl-2-nitroethenamine)]-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one.

Claim 7 (original): 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[N-[1-(*N', N'*-dimethyl-2-nitroethenamine)]-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one.

Claim 8 (original): 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[*N*-(*N'*-phenylcarbamoyl)-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-2-one.

Claim 9 (original): 9, 10-Dimethoxy-3-[2-guanidinoethyl]-2-(2,4,6-trimethylphenylimino)-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one.

Claim 10 (original): 9,10-Dimethoxy-3-[*N*-(*N'*-nitro)-2-guanidinoethyl]-2-(2,4,6-trimethylphenylimino)-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one.

Claim 11 (currently amended): 3-[*N*-(*N'*-Cyclohexylcarbamoyl)-2-aminoethyl]-9,10-dimethoxy-2-(2,4,6-trimethyl-phenylimino)-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one.

Claim 12 (original): 3-(*N*-Carbamoyl-2-aminoethyl)-9,10-dimethoxy-2-(2-methylphenylimino)-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one.

Claim 13 (original): 3-(*N*-Carbamoyl-2-aminoethyl)-2-(2,6-diisopropylphenylimino)-9,10-dimethoxy-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one.

Attorney Docket No.: 56476 (71661)
U.S.S.N.: 09/964,260


Inventors: Oxford, et al.
Filed: September 26, 2001
Page 5 of 11

Claim 14 (original): 3-(*N*-Carbamoyl-4-aminobutyl)-9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one.

Claim 15 (original): 3-[*N*-(*N'*-Cyano-*N''*-methyl)-2-guanidinoethyl]-9,10-dimethoxy-2-(2,4,6-trimethyl-phenylimino)-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one.

Claims 16-50 (cancelled).

Claim 51 (new): A composition comprising a compound of general formula I:



I

wherein

each of R¹ and R² independently represents a C₁₋₆ alkyl or C₂₋₇ acyl group;

R⁵ represents a hydrogen atom or a C₁₋₃ alkyl, C₂₋₃ alkenyl or C₂₋₃ alkynyl group;

R⁶ represents a hydrogen atom or a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, amino, C₁₋₆ alkylamino, di(C₁₋₆) alkylamino or C₂₋₇ acylamino group;

Attorney Docket No.: 56476 (71661)
U.S.S.N.: 09/964,260
Inventors: Oxford, et al.
Filed: September 26, 2001
Page 6 of 11

each of R⁷ and R⁸ independently represents a hydrogen or halogen atom or a hydroxy, trifluoromethyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₂₋₇ acyl, C₁₋₆ alkylthio, C₁₋₆ alkoxy, C₃₋₆ cycloalkyl; and

R⁹ represents a hydrogen or halogen atom or a hydroxy, trifluoromethyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₂₋₇ acyl, C₁₋₆ alkylthio, C₁₋₆ alkoxy or C₃₋₆ cycloalkyl group;

X represents OCH₂ or a group CR³R⁴, wherein each of R³ and R⁴ independently represents a hydrogen atom or a C₁₋₃ alkyl group;

each of R¹⁰ and R¹¹ independently represents a hydrogen atom, a C₁₋₃ alkyl, C₃₋₆ cycloalkyl or phenyl group;

Y represents an oxygen atom or a group CHNO₂, NCN, NH or NNO₂;

n is an integer from 2 to 4;

or a salt thereof;

and a veterinarianly or pharmaceutically acceptable carrier or diluent.

Claim 52 (new): A composition of claim 51, wherein independently or in any compatible combination:

each of R¹ and R² represents a C₁₋₆ alkyl;

R¹ and R² are the same as each other;

each of R³ and R⁴ represents a hydrogen atom;

R⁵ represents a hydrogen atom;

R⁶ represents a hydrogen atom;

each of R⁷ and R⁸ represents a C₁₋₆ alkyl;

R⁷ and R⁸ are the same as each other;

R⁹ represents a halogen atom or a methyl or acetyl group;

Attorney Docket No.: 56476 (71661)
U.S.S.N.: 09/964,260
Inventors: Oxford, et al.
Filed: September 26, 2001
Page 7 of 11

Y represents an oxygen atom or a group CHNO₂; and
n is 2.

Claim 53 (new): A composition of claim 52, wherein each of R¹ and R² represents a C₁₋₄ alkyl, group; and each of R⁷ and R⁸ represents a methyl, ethyl or isopropyl group.

Claim 54 (new): A composition of claim 2, wherein each of R¹ and R² represents a C₁₋₄ alkyl, group; and each of R⁷ and R⁸ represents a methyl, ethyl or isopropyl group.

Claim 55 (new): A composition as claimed in any one of claims 51 or 52, further comprising an active agent selected from the group consisting of a β₂-adrenoceptor agonist and a glucocorticoid steroid.

Claim 56 (original): A composition as claimed in claim 55, wherein the composition is a pharmaceutical composition for human medicine.

Claim 57 (new): A composition as claimed in claim 56, adapted for administration by aerosol.

Claim 58 (new): A composition comprising a compound selected from the group consisting of:

9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one;
9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[N-(N'-isopropylcarbamoyl)-2-aminoethyl]-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one;
9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[N-[1-(N'-methyl-2-nitroethenamine)]-2-aminoethyl]-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one;

Attorney Docket No.: 56476 (71661)

U.S.S.N.: 09/964,260

Inventors: Oxford, et al.

Filed: September 26, 2001

Page 8 of 11

9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[N-[1-(*N'*-isopropyl-2-nitroethenamine)]-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one;

9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[N-[1-(*N', N'*-dimethyl-2-nitroethenamine)]-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one;

9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-[N-(*N'*-phenylcarbamoyl)-2-aminoethyl]-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-2-one;

9, 10-Dimethoxy-3-[2-guanidinoethyl]-2-(2,4,6-trimethylphenylimino)-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one;

9,10-Dimethoxy-3-[N-(*N'*-nitro)-2-guanidinoethyl]-2-(2,4,6-trimethylphenylimino)-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one;

3-[N-(*N'*-Cyclohexylcarbamoyl)-2-aminoethyl]-9,10-dimethoxy-2-(2,4,6-trimethyl-phenylimino)-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one;

3-(*N*-Carbamoyl-2-aminoethyl)-9,10-dimethoxy-2-(2-methylphenylimino)- 3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one;

3-(*N*-Carbamoyl-2-aminoethyl)-2-(2,6-diisopropylphenylimino)-9,10-dimethoxy-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one;

3-(*N*-Carbamoyl-4-aminobutyl)-9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)- 3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one; and

3-[N-(*N'*-Cyano-*N''*-methyl)-2-guanidinoethyl]-9,10-dimethoxy-2-(2,4,6-trimethyl-phenylimino)-3,4,6,7-tetrahydro-2*H*-pyrimido[6,1-a]isoquinolin-4-one;

and a veterinarianily or pharmaceutically acceptable carrier or diluent.

Claim 59 (new): A composition as claimed in claim 58, further comprising an active agent selected from the group consisting of a β_2 -adrenoceptor agonist and a glucocorticoid steroid.

Attorney Docket No.: 56476 (71661)

U.S.S.N.: 09/964,260

Inventors: Oxford, et al.

Filed: September 26, 2001

Page 9 of 11

Claim 60 (original): A composition as claimed in claim 58, wherein the composition is a pharmaceutical composition for human medicine.

Claim 61 (new): A composition as claimed in claim 60, adapted for administration by aerosol.